ArticleDrug metabolism and disposition: the biological fate of chemicals2025
Downregulation of hepatic sulfotransferase 1E1 expression associated with decreased expression of multidrug resistance-associated protein 2.
Article in Drug metabolism and disposition: the biological fate of chemicals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Changes in the expression of drug-metabolizing enzymes and transporters can alter the pharmacokinetics of drugs, potentially affecting their efficacy and safety. In this study, we investigated the effects of decreased multidrug resistance-associated protein (MRP) 2 expression on the gene expression of other drug-metabolizing enzymes and transporters. Variations in the mRNA expression of drug-metabolizing enzymes and transporters were observed in MRP2-knockdown human hepatocellular carcinoma HepG2 cells and the liver of MRP2-deficient Eisai hyperbilirubinemic rats (EHBR). Both models showed decreased mRNA and protein expression of sulfotransferase (SULT) 1E1, a phase II drug-metabolizing enzyme, suggesting a relationship between the transcriptional regulation of MRP2 and SULT1E1. The plasma levels of bilirubin, bile acids, and cholesterol were higher in EHBR than in control Sprague-Dawley rats. Treatment with chenodeoxycholic acid (CDCA), a primary bile acid, reduced SULT1E1 mRNA expression in HepG2 cells and suppressed human SULT1E1 promoter activity in a luciferase reporter assay using HepG2 cells. CDCA is a known agonist of the farnesoid X receptor (FXR), and transcriptome analysis of the EHBR liver also suggested FXR activation, as inferred from changes in its target gene expression. These findings suggest that decreased MRP2 expression causes coordinated changes in the SULT1E1 gene expression via FXR activation by endogenous substances. These indirect changes in the expression of drug-metabolizing enzymes or transporters should be considered during drug development and in clinical practice. SIGNIFICANCE STATEMENT: This study investigated compensatory or coordinated changes in gene expression of drug-metabolizing enzymes and transporters in multidrug resistance-associated protein (MRP) 2-knockdown HepG2 cells and in the liver of MRP2-deficient rats. Decreased expression of MRP2 affects the gene expression of drug-metabolizing enzymes and transporters, including a decrease in SULT1E1, likely through nuclear receptor activation by endogenous molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.